People: Trius Therapeutics Inc (TSRX.W)


TSRX.W on CBOE When Trading NASDAQ Global Select Market

8.58USD
19 Jun 2013
Price Change (% chg)

$-0.04 (-0.46%)
Prev Close
$8.62
Open
$8.52
Day's High
$8.58
Day's Low
$8.48
Volume
600
Avg. Vol
3,022
52-wk High
$9.19
52-wk Low
$4.44

Search Stocks

Summary

Name Age Since Current Position

David Kabakoff

 64 2007 Independent Chairman of the Board

Jeffrey Stein

 57 2007 President, Chief Executive Officer, Director

John Schmid

 49 2004 Chief Financial Officer

John Finn

 56 2007 Chief Scientific Officer

Michael Morneau

 47 2010 Vice President - Finance, Chief Accounting Officer

Matthew Onaitis

 41 2013 General Counsel, Secretary

Kenneth Bartizal

 61 2007 Chief Development Officer

Philippe Prokocimer

 62 2007 Chief Medical Officer

J. Craig Thompson

 45 2011 Chief Commercial Officer

Seth Fischer

 2013 Director

Brian Atwood

 59 2007 Independent Director

Karin Eastham

 63 2009 Independent Director

Nina Kjellson

 37 2007 Independent Director

Brendan O'Leary

 40 2010 Independent Director

Theodore Schroeder

 57 2009 Independent Director

Paul Truex

 43 2008 Independent Director
» Insider Trading

Biographies

Name Description

David Kabakoff

 Dr. David S. Kabakoff, Ph.D. is Independent Chairman of the Board of Trius Therapeutica Inc. Dr. Kabakoff has served on the Board of Directors since March 2006 and has served as Chairman of the Board of Directors since February 2007. From May 2007 to December 2009, Dr. Kabakoff served as an Executive-in-Residence with Sofinnova Ventures, a venture capital firm, and he has served as an Executive Partner with Sofinnova Ventures since January 2010. Since August 2000, Dr. Kabakoff has served as the president of Strategy Advisors, LLC, a consulting firm. From January 2001 to June 2005, Dr. Kabakoff also served as the founder, chairman and chief executive officer of Salmedix, Inc., a biotechnology company, which was acquired by Cephalon, Inc. From May 1996 to August 2000, Dr. Kabakoff served in senior executive positions at Dura Pharmaceuticals Inc., a specialty pharmaceuticals company. Dr. Kabakoff currently serves as Chairman of Amplimmune, Inc. and on the Board of Directors of InterMune, Inc. Dr. Kabakoff holds a B.A. in Chemistry from Case Western Reserve University and a Ph.D. in Chemistry from Yale University.

Jeffrey Stein

 Dr. Jeffrey Stein, Ph.D., is President, Chief Executive Officer, Director of Trius Therapeutics Inc. Dr. Stein has served as the Company's president and Chief Executive Officer since February 2007 and on the Board of Directors since 2005. From 2005 through 2007, Dr. Stein was a Kauffman Fellow with the venture capital firm Sofinnova Ventures. He has served as a Venture Partner with Sofinnova Ventures from 2007 to 2010 and as Director of Venture Development for the University of California, San Diego from 2005 to 2006. From 1999 to 2005, Dr. Stein served as executive vice president, chief scientific officer and a member of the Board of Directors of Quorex Pharmaceuticals, an anti-infectives company he founded in 1999, which was acquired by Pfizer Inc. in 2005. From 1995 to 1999, Dr. Stein was a scientist with Diversa Corporation where he served as principal scientist and head of the anti-infectives discovery team. From 1993 to 1995, Dr. Stein served as Principal Scientist with the Agouron Institute, a private research institution, where he conducted research in bacterial genetics. From 1991 to 1993, he was an Alexander Hollaendar Distinguished Postdoctoral Fellow with the California Institute of Technology. Dr. Stein holds a Ph.D. in biochemistry and microbiology from the University of California, at San Diego.

John Schmid

 Mr. John P. Schmid has served as Chief Financial Officer of Trius Therapeutics Inc., since June 2004. He is a co-founder of company. From 1998 to 2003, Mr. Schmid served as the chief financial officer of GeneFormatics, Inc., a structural proteomics company, where he was a co-founder. From 1995 to 1998, Mr. Schmid served as the chief financial officer of Endonetics, Inc., a biotechnology company. From 1992 to 1995, Mr. Schmid was an associate with Idanta Partners, a venture capital firm. From 1987 to 1992, Mr. Schmid served as a vice president at Home Federal Bank. From 1985 to 1986, Mr. Schmid served as a financial analyst for Manufacturers Hanover Trust Company. In addition, from 1994 to 2005, Mr. Schmid served as a member of the board of directors and as president of the San Diego Venture Group in 1995. Mr. Schmid holds a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.

John Finn

 Dr. John Finn, Ph.D., is Chief Scientific Officer of Trius Therapeutics Inc., since February 2007. From July 2004 to February 2007, he served as the Company's president. From December 2003 to June 2004, Dr. Finn served as the vice president of drug discovery at Elitra Pharmaceuticals Inc., a biopharmaceutical company. From January 1998 to March 2003, Dr. Finn served as the senior director of lead discovery and optimization at Cubist Pharmaceuticals, Inc., a biopharmaceutical company. From January 1995 to December 1997, Dr. Finn served as associate director at Synaptic Pharmaceutical Corporation, a biopharmaceutical company. From December 1984 to January 1995, Dr. Finn served as the senior scientist of American Cyanamid Company. Dr. Finn holds a B.S. in chemistry from Villanova University and a Ph.D. from the University of Illinois.

Michael Morneau

 Mr. Michael Morneau is Vice President - Finance and Chief Accounting Officer of Trius Therapeutics Inc. Mr. Morneau joined the company in December 2009 as Senior Finance Director and Corporate Controller. In August 2010, he was promoted to Vice President of Finance and Chief Accounting Officer. Prior to joining Trius, in 2008 and 2009 he was a Finance Director at Eli Lilly and Company within Lilly Research Labs in San Diego. From 2006 to 2008, Mr. Morneau was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company that was acquired by Eli Lilly. From 2004 to 2006, he was Controller at Momenta Pharmaceuticals, Inc., a biotechnology company. From 2003 to 2004, Mr. Morneau was Corporate Controller at Gensym Corporation, a software company. Prior to 2003, Mr. Morneau spent ten years at PricewaterhouseCoopers LLP, and its predecessors in various positions of continuing responsibility, the last five years of which as a manager of business assurance in the firm’s technology practice. Mr. Morneau is a C.P.A. and holds a Bachelor’s degree in Mathematics from the University of New Hampshire and Master’s degrees in Accounting and Business Administration from Southern New Hampshire University (formerly New Hampshire College).

Matthew Onaitis

 Mr. Matthew W. Onaitis has been appointed as the General Counsel, Secretary of Trius Therapeutics, Inc., with effect from June 3, 2013. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. where he led the legal, compliance and business development functions. Prior to his seven years at Somaxon, Mr. Onaitis served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.

Kenneth Bartizal

 Dr. Kenneth Bartizal, Ph.D. is Chief Development Officer of Trius Therapeutics Inc., since June 2007. From 1988 to 2007, he served as executive director and head of infectious disease research at Merck & Co., Inc., a pharmaceutical company. From 1986 to 1988, Dr. Bartizal served as a research scientist at Pfizer Inc., a pharmaceutical company. From 1983 to 1986, he was a faculty member and conducted research at the Kirksville College of Osteopathic Medicine and Northeast Missouri State University. Dr. Bartizal holds a B.S. in Professional Studies, an M.S. in Physiology and a Ph.D. in Microbiology and Biochemistry from the University of Notre Dame. Dr. Bartizal performed postdoctoral research at the University of Wisconsin from 1981 to 1983.

Philippe Prokocimer

 Dr. Philippe G. Prokocimer, M.D., is Chief Medical Officer of Trius Therapeutics Inc., since July 2007. From 2003 to 2007, he served as a vice president, clinical research at Johnson & Johnson Pharmaceutical Research and Development, L.L.C. From 2001 to 2003, Dr. Prokocimer served as vice president, clinical research at Maxim Pharmaceuticals, Inc., a biopharmaceutical company, and from 1994 to 2001, he served as vice president of anti-infectives clinical research at Aventis Pharmaceuticals, Inc., a pharmaceutical company. From 1987 to 1994, Dr. Prokocimer served as associate medical director for Abbott Laboratories, a healthcare company. Dr. Prokocimer is board certified in Anesthesiology and Critical Care Medicine from Centre Hospitalier-Universitaire Bichat-Beaujon. He holds an M.D. from the School of Medicine (Centre Hospitalier-Universitaire Pitie-Salpetriere) in Paris, France and undertook his post-doctoral research fellowship in adrenergic pharmacology at Stanford University from 1984 to 1986.

J. Craig Thompson

 Mr. J. Craig Thompson is Chief Commercial Officer of Trius Therapeutics, Inc. From 2003 to 2011, Mr. Thompson served in various Global and US Commercial roles with Pfizer Inc., and most recently held the position of Vice President of Marketing for Pfizer’s Specialty Care Business Unit where he was directly responsible for the U.S. commercial strategy for products with over $1.5 billion in annual U.S. sales. From 1992 to 2003, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc., where he most notably worked on the commercial planning and marketing activities for the company’s anti-infectives as well as on cardiovascular brands. Mr. Thompson holds a Bachelor’s degree in Commerce from McMaster University and an MBA from the University of Notre Dame.

Seth Fischer

 Mr. Seth H. Z. Fischer has been appointed as Director of Trius Therapeutics Inc., effective April 3, 2013. Mr. Fischer was the former Company Group Chairman Johnson & Johnson, Worldwide Franchise Chairman Cordis Corporation responsible for the Cardiovascular Device Business until his retirement in 2012. He has three decades of healthcare experience in the pharmaceutical and medical device industry. Mr. Fischer served in positions of increasing responsibility with Johnson & Johnson until his retirement in 2012. Most recently Mr. Fischer served as Company Group Chairman Johnson & Johnson, Worldwide Franchise Chairman Cordis Corporation from 2008 to 2012, which included responsibility for Cordis and Biosense Webster. Previously, he served as Company Group Chairman North America Pharmaceuticals from 2004 to 2007. In this position he had responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Prior to this position, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals from 2000 to 2004. His operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including the oral and IV anti-infectives Levaquin® and Floxin®, cardiovasculars, CNS, analgesics and women’s health.

Brian Atwood

 Mr. Brian G. Atwood is Independent Director of Trius Therapeutics Inc., since February 2007. Mr. Atwood has been a managing director and co-founder of Versant Ventures, a venture capital firm, since 1999. Since 1997, he has also been a general partner at Brentwood Venture Capital, a venture capital firm. From 1993 to 1995, Mr. Atwood served as president and chief executive officer of Glycomed, Inc., a publicly traded biotechnology company, of which he was a founder. Mr. Atwood also co-founded and served as member of the Board of Directors of Perkin Elmer/Cetus Instruments, a joint venture for robotics automation and genomics research instruments. Mr. Atwood currently serves on the Board of Directors of Cadence Pharmaceuticals, Inc. and Helicos Biosciences Corporation. Mr. Atwood holds a B.S. in Biological Sciences from the University of California, Irvine, a Master’s degree from the University of California, Davis, and an M.B.A. from Harvard Business School.

Karin Eastham

 Ms. Karin Eastham, CPA, is Independent Director of Trius Therapeutics Inc., since November 2009. From May 2004 to September 2008, she served as executive vice president and chief operating officer, and as a member of the board of trustees of the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From April 1999 to May 2004, Ms. Eastham served as senior vice president, finance, chief financial officer and secretary of Diversa Corporation, a publicly held renewable energy company which was subsequently renamed Verenium Corporation. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including vice president, finance, at Boehringer Mannheim Corporation from 1976 to 1988. Ms. Eastham also serves as a director for Amylin Pharmaceuticals, Inc., Geron Corporation and Illumina, Inc. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant and a Certified Director.

Nina Kjellson

 Ms. Nina Kjellson is Independent Director of Trius Therapeutics Inc., since February 2007. Ms. Kjellson is a managing director at InterWest Partners, a venture capital firm, where she has been employed since 2002. From June 2000 to June 2002, she served as an investment manager at Bay City Capital, a life sciences merchant bank, and from October 1999 to June 2000, as a research associate at Oracle Partners, a healthcare-focused hedge fund. From August 1997 to September 1999, Ms. Kjellson conducted health policy and survey research with the Kaiser Family Foundation, a private foundation focusing on healthcare issues. She holds a B.A. in Human Biology from Stanford University.

Brendan O'Leary

 Dr. Brendan O'Leary, Ph.D., is Independent Director of Trius Therapeutics, Inc., since September 1, 2010. Dr. O’Leary served on the board of directors from February 2007 to March 2008 and then re-joined the board in September 2010. Dr. O’Leary is a managing member of Prism VentureWorks and focuses on investments in the pharmaceutical, medical device, and diagnostic sectors. He was formerly on the boards of several venture-backed companies including Atritech, BioRexis Pharmaceutical Corporation, Serica Technologies, Inc. and he currently serves on several other boards in the life sciences sector. Dr. O’Leary has over a dozen years of experience in the biotechnology and medical technology arenas and has held senior operating positions at companies such as Meso Scale Discovery and IGEN International. He is also an accomplished scientist with numerous publications, inventions and commercialized products to his credit. Dr. O’Leary received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology. He holds a B.A. in Chemistry and Economics from Middlebury College. Dr. O’Leary was also a Kauffman Fellow.

Theodore Schroeder

 Mr. Theodore R. Schroeder is Independent Director of Trius Therapeutics Inc. Since May 2004, Since May 2004, Mr. Schroeder has served as President and Chief Executive Officer and as a member of the Board of Directors of Cadence Pharmaceuticals, Inc., a biopharmaceutical company. From August 2002 to February 2004, Mr. Schroeder served as Senior Vice President, North American Sales and Marketing of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company. From February 2001 to August 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan. Mr. Schroeder held the position of Senior Director of Marketing Hospital Products at Dura Pharmaceuticals, Inc., a specialty respiratory pharmaceutical and pulmonary drug delivery company, from May 1999 to November 2000 until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder currently serves on the Board of Directors of the Sharp Hospital Foundation and holds a B.S. in management from Rutgers University.

Paul Truex

 Mr. Paul F. Truex is Independent Director of Trius Therapeutics Inc., since February 2008. Since September 2004, Mr. Truex has been the president and chief executive officer of Anthera Pharmaceuticals, Inc., a pharmaceutical company, which he founded. From October 2001 to September 2004, Mr. Truex served as a member of the Board of Directors and president and chief executive officer of Peninsula Pharmaceuticals, Inc., a biopharmaceutical company. From April 2000 to September 2001, Mr. Truex was vice president of commercial development of Vicuron, Inc., a biopharmaceutical company. From July 1997 to April 2000, Mr. Truex held various positions at Eli Lilly and Company, a pharmaceutical company. Mr. Truex currently serves on the Board of Directors of Anthera Pharmaceuticals, Inc. and Eiger Biopharmaceuticals, Inc. Mr. Truex holds an M.B.A. in marketing and finance from Indiana University and a B.A. in economics from the University of Waterloo.

Insider Trading

Name Shares Traded Price

FINN JOHN M

 3,000 $9.08

FINN JOHN M

 1,000 $8.94

BARTIZAL KENNETH

 2,000 $7.90

PROKOCIMER PHILIPPE G

 2,000 $7.75

BARTIZAL KENNETH

 12,000 $7.93

PROKOCIMER PHILIPPE G

 12,000 $7.93

MORNEAU MICHAEL

 20,000 $4.00

BARTIZAL KENNETH

 12,000 $7.85

MORNEAU MICHAEL

 20,000 $7.75

FINN JOHN M

 5,000 $8.10

PROKOCIMER PHILIPPE G

 12,000 $7.65

STACK RISA

 591 $0.00

KPCB PANDEMIC & BIO DEFENSE FUND L L C

 680,850 $0.00

FINN JOHN M

 3,000 $7.48

KPCB PBD FOUNDERS FUND L L C

 4,050 $0.00

FINN JOHN M

 500 $7.10

FINN JOHN M

 1,500 $7.10

SCHMID JOHN P

 1,800 $6.00

STEIN JEFFREY

 38,462 $0.52

EASTHAM KARIN

 6,000 $3.50

SCHMID JOHN P

 5,000 $1.29

O LEARY BRENDAN

 9,302 $1.29

O LEARY BRENDAN

 12,000 $4.00

POWELL MICHAEL F

 9,302 $1.29

FINN JOHN M

 20,000 $0.52
» Full list on Insider Trading
Search Stocks